Cardiff Lateral Drilling of Clayton Well Nearing Completion

Spotlight Companies  |

Cardiff Energy Corp ($CRS:CA) announced that the Lateral drilling of the Clayton No. 1H, currently residing at 6,500 feet, will be completed this weekend. Also, in their partnership with project operator Martin Energies, Cardiff has acquired an additional 10% working interest in the Clayton No.1H.

"We are elated with the drilling results to date and are extremely excited to have increased our working interest in Clayton No. 1H to 60%,” said Jack Bal, president and CEO of Cardiff. “With funding secured and the well scheduled to be completed this weekend, we are looking forward to the initial flow test."

The Texas-based Clayton well, planned as a follow-up to the successful drilling of Bearcat 4, was designed to test the Gardener Lime, a fractured limestone target. "During the past few days of drilling, numerous impressive gas kicks and oil shows were encountered,” said Martin Energies. “The deeper into the zone we drill, the formation appears to be much richer in hydrocarbons. With drilling scheduled to be completed this weekend, we are looking forward to testing the well."

With Cardiff’s focus on the acquisition, exploration, development, and production of oil and gas properties in the United States of America, the emerging junior oil and gas company is moving steadily along with their mission to identify oil and gas investment opportunities and strengthening shareholder value.

For more information about Cardiff Energy, visit

Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…